MX2023006777A - Composiciones y métodos que comprenden antagonistas de proteína 2 relacionada con frizzled secretada (sfrp2). - Google Patents

Composiciones y métodos que comprenden antagonistas de proteína 2 relacionada con frizzled secretada (sfrp2).

Info

Publication number
MX2023006777A
MX2023006777A MX2023006777A MX2023006777A MX2023006777A MX 2023006777 A MX2023006777 A MX 2023006777A MX 2023006777 A MX2023006777 A MX 2023006777A MX 2023006777 A MX2023006777 A MX 2023006777A MX 2023006777 A MX2023006777 A MX 2023006777A
Authority
MX
Mexico
Prior art keywords
sfrp2
antigen
compositions
binding fragments
antagonists
Prior art date
Application number
MX2023006777A
Other languages
English (en)
Inventor
Nancy Demore
Cam Patterson
Original Assignee
Univ North Carolina Chapel Hill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ North Carolina Chapel Hill filed Critical Univ North Carolina Chapel Hill
Publication of MX2023006777A publication Critical patent/MX2023006777A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente descripción proporciona anticuerpos humanizados y fragmentos de unión al antígeno de estos que se unen específicamente a SFRP2 y composiciones que comprenden los anticuerpos humanizados o fragmentos de unión al antígeno de estos. En algunos aspectos, los anticuerpos humanizados o los fragmentos de unión al antígeno pueden usarse para tratar enfermedades o afecciones asociadas con un aumento de SFRP2, como el cáncer. En algunos aspectos, los anticuerpos o fragmentos de unión al antígeno pueden usarse para tratar el osteosarcoma.
MX2023006777A 2020-12-11 2021-12-10 Composiciones y métodos que comprenden antagonistas de proteína 2 relacionada con frizzled secretada (sfrp2). MX2023006777A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063124345P 2020-12-11 2020-12-11
PCT/US2021/062854 WO2022125927A1 (en) 2020-12-11 2021-12-10 Compositions and methods comprising sfrp2 antagonists

Publications (1)

Publication Number Publication Date
MX2023006777A true MX2023006777A (es) 2023-08-17

Family

ID=81974701

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023006777A MX2023006777A (es) 2020-12-11 2021-12-10 Composiciones y métodos que comprenden antagonistas de proteína 2 relacionada con frizzled secretada (sfrp2).

Country Status (10)

Country Link
US (2) US11873333B2 (es)
EP (1) EP4259203A1 (es)
JP (1) JP2023553938A (es)
KR (1) KR20230118904A (es)
CN (1) CN116744970A (es)
AU (1) AU2021396381A1 (es)
CA (1) CA3201893A1 (es)
IL (1) IL303600A (es)
MX (1) MX2023006777A (es)
WO (1) WO2022125927A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3201893A1 (en) 2020-12-11 2022-06-16 The University Of North Carolina At Chapel Hill Compositions and methods comprising sfrp2 antagonists

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
JP2532858B2 (ja) 1985-04-01 1996-09-11 セルテツク リミテツド 形質転換したミエロ―マ細胞系
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
US20040014194A1 (en) 2002-03-27 2004-01-22 Schering Corporation Beta-secretase crystals and methods for preparing and using the same
CA2697193C (en) 2007-09-14 2017-06-06 Adimab, Inc. Rationally designed, synthetic antibody libraries and uses therefor
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
EP2285989B1 (en) 2008-05-15 2016-11-16 The University of North Carolina At Chapel Hill Novel targets for regulation of angiogenesis
WO2011119524A1 (en) 2010-03-22 2011-09-29 The University Of North Carolina At Chapel Hill Novel targets for regulation of angiogenesis
AU2011279073B2 (en) 2010-07-16 2016-06-09 Adimab, Llc Antibody libraries
EP3044590A4 (en) 2013-09-13 2017-09-20 The University of North Carolina at Chapel Hill Methods and compositions for tumor vasculature imaging and targeted therapy
CA3201893A1 (en) 2020-12-11 2022-06-16 The University Of North Carolina At Chapel Hill Compositions and methods comprising sfrp2 antagonists

Also Published As

Publication number Publication date
CA3201893A1 (en) 2022-06-16
US11873333B2 (en) 2024-01-16
AU2021396381A1 (en) 2023-07-06
IL303600A (en) 2023-08-01
CN116744970A (zh) 2023-09-12
US20220204598A1 (en) 2022-06-30
KR20230118904A (ko) 2023-08-14
WO2022125927A1 (en) 2022-06-16
US20240190949A1 (en) 2024-06-13
JP2023553938A (ja) 2023-12-26
EP4259203A1 (en) 2023-10-18

Similar Documents

Publication Publication Date Title
ZA202211057B (en) Anti-trem2 antibodies and methods of use thereof
PH12020500671A1 (en) Antibodies specific for gucy2c and uses thereof
WO2017062672A3 (en) Anti-trem2 antibodies and methods of use thereof
CR20200467A (es) Agentes anticuerpos anti-cd25
PH12021550337A1 (en) Anti-gdf15 antibodies, compositions and methods of use
WO2017075432A3 (en) Anti-siglec-9 antibodies and methods of use thereof
EA201792221A1 (ru) Антитела против сортилина и способы их применения
NZ738979A (en) Pd-1 antibodies
PH12020551930A1 (en) Anti-sirpa antibodies and methods of use thereof
PH12018550179A1 (en) Anti-pd-1 antibodies, method for producing same and method for using same
PH12021550041A1 (en) Anti-sortilin antibodies and methods of use thereof
MX2021001268A (es) Anticuerpos anti-btn3a y su uso en el tratamiento del cáncer o trastornos infecciosos.
MX2020013324A (es) Anticuerpos anti proteína reguladora de señales beta 1 (sirp-beta1) y métodos de uso de los mismos.
MX2022002682A (es) Anticuerpos anti-cd73.
MX2022015258A (es) Anticuerpos anti-cxcr5 y composiciones y usos de los mismos.
PH12020551323A1 (en) Anti cd6 antibodies for treating severe asthma
MX2021000933A (es) Anticuerpos anti-siglec-5 y métodos para su uso.
WO2022051591A3 (en) Nectin-4 antibodies and uses thereof
MX2019009498A (es) Anticuerpos mimeticos de fgf21 y usos de los mismos.
MX2021010116A (es) Anticuerpo anti-pd-l1 y uso de este.
MX2023006777A (es) Composiciones y métodos que comprenden antagonistas de proteína 2 relacionada con frizzled secretada (sfrp2).
MX2022010021A (es) Anticuerpos de pilra y sus metodos de uso.
PH12020551451A1 (en) Anti-cd25 for tumour specific cell depletion
MX2020011377A (es) Metodos y composiciones para el tratamiento de urticaria cronica.
MX2022003523A (es) Proteinas de union a antigenos.